To Evaluate Efficacy of Monotherapy of Oxcarbazepine Versus Combination of Gabapentin With Oxcarbazepine in the Management of Trigeminal Neuralgia
Key facts
- Phase
- Phase 2/3
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Rehman Medical Institute - RMI
- Trial code
- NCT07625410
- Record updated
- 4 June 2026
- Original description
ABSTRACT:Read full original descriptionShow less
To Evaluate Efficacy of Monotherapy of Oxcarbazepine Versus Combination of Gabapentin With Oxcarbazepine in the Management of Trigeminal Neuralgia.
ABSTRACT:
Objective: This study evaluates the effectiveness of oxcarbazepine monotherapy with the combination of gabapentin and oxcarbazepine in managing trigeminal neuralgia(TN).
Methods: A prospective observational study was conducted at Rehman College of Dentistry for the duration of one year, i.e., from 1st May 2023 till May 2024. A total of 44 patients, fulfilling inclusion criteria, were included.Half were given monotherapy with oxcarbazepine (300 mg twice daily) and half were given combination therapy with gabapentin (100 mg daily) plus oxcarbazepine. Pain was evaluated utilizing the Visual Analogue Scale (VAS) at baseline, 2 weeks, and 2 months. SPSS software version 26 was used for statistical analysis.
KEYWORDS: Combination Therapy, Gabapentin, Monotherapy, Oxcarbazepine, Trigeminal Neuralgia, Visual Analogue Scale.
Inclusion: Patients of either gender aged 20-80 years; Patients presenting to the Outpatient Department (OPD); Patients fulfilling the diagnostic criteria for idiopathic trigeminal neuralgia according to the International Headache Society (IHS).
Exclusion: Patients with a history of previous surgical procedures for neuralgia; Patients with orofacial or odontogenic pain conditions other than trigeminal neuralgia (TN); Patients with temporomandibular joint (TMJ) disorders; Patients with known allergy to medications used for neuralgia; Patients with significant comorbid medical conditions; Patients with a centralized cause of TN evident on MRI; Patients unwilling to participate in the study; Patients who failed to attend follow-up visits; Pregnant or lactating females.